Chi KN - Search Results

1

A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer.

Winquist E, Moore MJ, Chi KN, Ernst DS, Hirte H, North S, Powers J, Walsh W, Boucher T, Patton R, Seymour L. Winquist E, et al. Among authors: chi kn. Urol Oncol. 2005 May-Jun;23(3):143-9. doi: 10.1016/j.urolonc.2004.12.012. Urol Oncol. 2005. PMID: 15907712 Clinical Trial.

2

Carboplatin and vinblastine for the treatment of metastatic transitional cell carcinoma of the urothelial tract.

Al-Karim HA, Tan KE, Chi KN, Bryce CJ, Murray NR, Coppin C. Al-Karim HA, et al. Among authors: chi kn. Am J Clin Oncol. 2002 Oct;25(5):515-9. doi: 10.1097/00000421-200210000-00019. Am J Clin Oncol. 2002. PMID: 12393996

3

Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group.

Townsley CA, Chi K, Ernst DS, Belanger K, Tannock I, Bjarnason GA, Stewart D, Goel R, Ruether JD, Siu LL, Jolivet J, McIntosh L, Seymour L, Moore MJ; National Cancer Institute of Canada-Clinical Trials Group. Townsley CA, et al. J Clin Oncol. 2003 Apr 15;21(8):1524-9. doi: 10.1200/JCO.2003.03.057. J Clin Oncol. 2003. PMID: 12697876 Clinical Trial.

4

Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain.

Ernst DS, Tannock IF, Winquist EW, Venner PM, Reyno L, Moore MJ, Chi K, Ding K, Elliott C, Parulekar W. Ernst DS, et al. J Clin Oncol. 2003 Sep 1;21(17):3335-42. doi: 10.1200/JCO.2003.03.042. J Clin Oncol. 2003. PMID: 12947070 Clinical Trial.

5

A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer.

Chi KN, Eisenhauer E, Fazli L, Jones EC, Goldenberg SL, Powers J, Tu D, Gleave ME. Chi KN, et al. J Natl Cancer Inst. 2005 Sep 7;97(17):1287-96. doi: 10.1093/jnci/dji252. J Natl Cancer Inst. 2005. PMID: 16145049 Clinical Trial.

6

A phase I dose finding study of cisplatin, gemcitabine, and weekly docetaxel for patients with advanced transitional cell cancer.

Tinker A, Winquist E, Canil C, Moore M, Murray RN, Chi KN. Tinker A, et al. Among authors: chi kn. Am J Clin Oncol. 2006 Feb;29(1):3-7. doi: 10.1097/01.coc.0000200044.81711.57. Am J Clin Oncol. 2006. PMID: 16462494 Clinical Trial.

7

A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer.

Chi KN, Siu LL, Hirte H, Hotte SJ, Knox J, Kollmansberger C, Gleave M, Guns E, Powers J, Walsh W, Tu D, Eisenhauer E. Chi KN, et al. Clin Cancer Res. 2008 Feb 1;14(3):833-9. doi: 10.1158/1078-0432.CCR-07-1310. Clin Cancer Res. 2008. PMID: 18245546 Clinical Trial.

8

Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer.

Chi KN, Chin JL, Winquist E, Klotz L, Saad F, Gleave ME. Chi KN, et al. J Urol. 2008 Aug;180(2):565-70; discussion 570. doi: 10.1016/j.juro.2008.04.012. Epub 2008 Jun 12. J Urol. 2008. PMID: 18554663 Clinical Trial.

9

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK. Heng DY, et al. Among authors: chi kn. J Clin Oncol. 2009 Dec 1;27(34):5794-9. doi: 10.1200/JCO.2008.21.4809. Epub 2009 Oct 13. J Clin Oncol. 2009. PMID: 19826129

10

A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer.

Sridhar SS, Canil CM, Chi KN, Hotte SJ, Ernst S, Wang L, Chen EX, Juhasz A, Yen Y, Murray P, Zwiebel JA, Moore MJ. Sridhar SS, et al. Among authors: chi kn. Cancer Chemother Pharmacol. 2011 Apr;67(4):927-33. doi: 10.1007/s00280-010-1389-7. Epub 2010 Jul 3. Cancer Chemother Pharmacol. 2011. PMID: 20602233 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

278 results

Search Page

Filters